The rise of Viagra initially sparked a boom for the drug industry, however recent developments present a complicated scenario for investors. Off-patent alternatives are eroding profits, and ongoing patent challenges add further difficulty to the landscape. While specific companies might still gain from adjacent products, the overall trajectory sugg